Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

Confo Therapeutics appoints Paolo Vicini as Chief Development Officer

Details
Published: 04 June 2020
  • portfolio-news

Confo Therapeutics today announced the appointment of Paolo Vicini in the newly-created position of CDO effective June 1, 2020.With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini will apply his experience in translational and clinical sciences to support the Company as it moves its GPCR modulating small molecules through preclinical studies and into the clinic.

Wellington Partners’s portfolio company Themis to be acquired by MSD

Details
Published: 26 May 2020
  • portfolio-news

Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

Details
Published: 14 May 2020
  • portfolio-news

Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris.

  1. UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
  2. GTX Medical appoints John Murphy as Chief Technology Officer
  3. Themis announces Iain Dukes to join the company’s supervisory board
  4. STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer

Page 7 of 35

  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End
© Wellington Partners, 2021.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy